This review article discusses the development and application of new clinical trial designs in precision medicine, including basket, umbrella, and platform trials. These designs aim to improve the efficiency and personalization of clinical trials by focusing on biomarkers and molecular characteristics of diseases. Traditional clinical trials often use a one-size-fits-all approach, which may not be effective for all patients. In contrast, new trial designs allow for the evaluation of multiple interventions and treatments based on specific biomarkers, enabling more targeted and effective therapies. Basket trials evaluate the efficacy of a single drug or intervention across multiple diseases or tissue types that share a common molecular characteristic. Umbrella trials, on the other hand, evaluate multiple interventions for a single disease, stratifying patients based on their molecular profiles. Platform trials are a more flexible and adaptive design that allows for the continuous evaluation of multiple interventions and the ability to add or remove interventions based on accumulating evidence. The article highlights the importance of these new trial designs in precision medicine, as they enable the identification of biomarker-guided therapies that can be more effective for individual patients. The review also discusses the future directions of these trial designs, including the concepts of "precision pro," "dynamic precision," and "intelligent precision." These concepts emphasize the need for ongoing adaptation and innovation in clinical trial designs to better meet the needs of patients and advance precision medicine. The review concludes that these new trial designs have the potential to significantly improve the efficiency and effectiveness of clinical trials, leading to better outcomes for patients.This review article discusses the development and application of new clinical trial designs in precision medicine, including basket, umbrella, and platform trials. These designs aim to improve the efficiency and personalization of clinical trials by focusing on biomarkers and molecular characteristics of diseases. Traditional clinical trials often use a one-size-fits-all approach, which may not be effective for all patients. In contrast, new trial designs allow for the evaluation of multiple interventions and treatments based on specific biomarkers, enabling more targeted and effective therapies. Basket trials evaluate the efficacy of a single drug or intervention across multiple diseases or tissue types that share a common molecular characteristic. Umbrella trials, on the other hand, evaluate multiple interventions for a single disease, stratifying patients based on their molecular profiles. Platform trials are a more flexible and adaptive design that allows for the continuous evaluation of multiple interventions and the ability to add or remove interventions based on accumulating evidence. The article highlights the importance of these new trial designs in precision medicine, as they enable the identification of biomarker-guided therapies that can be more effective for individual patients. The review also discusses the future directions of these trial designs, including the concepts of "precision pro," "dynamic precision," and "intelligent precision." These concepts emphasize the need for ongoing adaptation and innovation in clinical trial designs to better meet the needs of patients and advance precision medicine. The review concludes that these new trial designs have the potential to significantly improve the efficiency and effectiveness of clinical trials, leading to better outcomes for patients.